GIA
SUPN icon

Gargoyle Investment Advisor’s Supernus Pharmaceuticals SUPN Stock Holding History

Gargoyle Investment Advisor’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-39,110
Closed -$549K – 178
2015
Q3 		$549K Buy
39,110
+3,843
+11% +$71.5K 0.23% 133
2015
Q2 		$599K Buy
+35,267
New +$502K 0.23% 126

Other funds holding SUPN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Gargoyle Investment Advisor's SUPN Position: Q4 2015 in Review

Gargoyle Investment Advisor sold out of Supernus Pharmaceuticals (SUPN) in Q4 2015, closing a stake of 39,110 shares — an estimated $549K sold.

Gargoyle Investment Advisor first reported a position in SUPN in Q2 2015 and held it in 2 quarters. The position peaked at $599K in Q2 2015. 209 funds tracked by Wall St. Rank hold SUPN as of Q4 2015.

  • Gargoyle Investment Advisor reported no remaining Supernus Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Gargoyle Investment Advisor sold 39,110 Supernus Pharmaceuticals shares in Q4 2015, an estimated $549K.
  • Gargoyle Investment Advisor first reported a position in Supernus Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Gargoyle Investment Advisor's Supernus Pharmaceuticals position peaked at $599K in Q2 2015.
  • 209 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2015.

Based on Gargoyle Investment Advisor's 13F filing for Q4 2015, filed 27 Jan 2016.